


consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

The preferred indications using the compounds of the present disclosure are depression, psychosis, Parkinson's disease, anxiety and attention deficit hyperactivity disorder (ADHD) and
5 diabetes.

In a first aspect, there is provided a compound of formula



I

wherein

- R^1 is ~~phenyl, optionally substituted by halogen, C_{1-7} -alkyl, C_{3-6} -cycloalkyl, C_{1-7} -alkoxy, cyano, C_{1-7} -alkyl substituted by halogen, C_{1-7} -alkyl substituted by hydroxy, C_{1-7} -alkoxy substituted by halogen or C_{1-7} -alkoxy substituted by hydroxy; or is~~
10 ~~pyridine-2, 3 or 4-yl, optionally substituted by halogen, C_{1-7} -alkyl, C_{3-6} -cycloalkyl, cyano, C_{1-7} -alkyl substituted by halogen, C_{1-7} -alkyl substituted by hydroxyl, C_{1-7} -alkoxy, C_{1-7} -alkoxy substituted by halogen, or C_{1-7} -alkoxy substituted by hydroxyl; or is~~
15 ~~pyrimidin-2, 4 or 5-yl, optionally substituted by halogen, C_{1-7} -alkyl, C_{3-6} -cycloalkyl, C_{1-7} -alkyl substituted by hydroxy or C_{1-7} -alkyl substituted by halogen, or is~~
~~pyrazin-2-yl, optionally substituted by halogen, C_{1-7} -alkyl, C_{3-6} -cycloalkyl, C_{1-7} -alkyl substituted by halogen, C_{1-7} -alkyl substituted by hydroxy or cyano, or is~~
~~2,2-difluorobenzo[d][1,3]dioxol-5-yl, or is~~
20 ~~thiazolyl, optionally substituted by C_{1-7} -alkyl substituted by halogen;~~


R^2 is hydrogen or C_{1-7} -alkyl;

R^3 is hydrogen, amino or C_{1-7} -alkyl;

Z is a bond, $-CH_2-$ or $-O-$;


or a pharmaceutically suitable acid addition salt thereof.

In a second aspect, there is provided a process for the manufacture of a compound of formula I as defined herein, which process comprises cleaving off the protecting group of compounds of formula



4

5 to form a compound of formula I



I

and, if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts, wherein the substituents are as described herein.

10 ~~In a third aspect, there is provided a compound as defined herein, when manufactured by a process as defined herein.~~

In a ~~fourth~~ third aspect, there is provided a pharmaceutical composition comprising a compound as defined herein and a pharmaceutical acceptable carrier and/or adjuvant.


In a ~~fifth~~ fourth aspect, there is provided compounds as defined herein for use as therapeutic active substances.

15 In a ~~sixth~~ fifth aspect, there is provided compounds as defined herein for use in the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic
20 complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

In a ~~seventh~~ sixth aspect, there is provided use of a compound as defined herein for the preparation of medicaments for the therapeutic and/or prophylactic treatment of depression,
25 anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-

Claims


1. A compound of formula



wherein

- 5 R^1 is ~~phenyl, optionally substituted by halogen, C_{1-7} -alkyl, C_{3-6} -cycloalkyl, C_{1-7} -alkoxy, cyano, C_{1-7} -alkyl substituted by halogen, C_{1-7} -alkyl substituted by hydroxy, C_{1-7} -alkoxy substituted by halogen or C_{1-7} -alkoxy substituted by hydroxy;~~ or is
pyridine-2, 3 or 4-yl, optionally substituted by halogen, C_{1-7} -alkyl, C_{3-6} -cycloalkyl, cyano,
 C_{1-7} -alkyl substituted by halogen, C_{1-7} -alkyl substituted by hydroxyl, C_{1-7} -alkoxy, C_{1-7} -
10 alkoxy substituted by halogen, or C_{1-7} -alkoxy substituted by hydroxyl; or is
pyrimidin-2, 4 or 5-yl, optionally substituted by halogen, C_{1-7} -alkyl, C_{3-6} -cycloalkyl, C_{1-7} -
alkyl substituted by hydroxy or C_{1-7} -alkyl substituted by halogen, or is
pyrazin-2-yl, optionally substituted by halogen, C_{1-7} -alkyl, C_{3-6} -cycloalkyl, C_{1-7} -alkyl
substituted by halogen, C_{1-7} -alkyl substituted by hydroxy or cyano, or is
15 2,2-difluorobenzo[d][1,3]dioxol-5-yl, or is
thiazolyl, optionally substituted by C_{1-7} -alkyl substituted by halogen;
- R^2 is hydrogen or C_{1-7} -alkyl;
 R^3 is hydrogen, amino or C_{1-7} -alkyl;
Z is a bond, $-CH_2-$ or $-O-$;
- 20 or a pharmaceutically suitable acid addition salt thereof.

~~2. A compound of formula IA according to claim 1,~~



wherein

R^2 — is hydrogen or C_{1-7} -alkyl;

R^3 — is hydrogen, amino or C_{1-7} -alkyl;

- 5 R^4 — is hydrogen, halogen, C_{1-7} -alkyl, C_{3-6} -cycloalkyl, C_{1-7} -alkoxy, cyano, C_{1-7} -alkyl substituted by halogen, C_{1-7} -alkyl substituted by hydroxyl, C_{1-7} -alkoxy substituted by halogen or C_{1-7} -alkoxy substituted by hydroxy;

n — is 1 or 2

Z — is a bond, CH_2 — or —O—;

- 10 or a pharmaceutically suitable acid addition salt thereof.

3. A compound according to any one of claims 1 or 2, wherein the compounds are

(S)- 5-methyl-N-(4-(morpholin-2-yl)phenyl)-1-phenyl-1H-pyrazole-4-carboxamide

(S)- 5-amino-1-(4-fluorophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)- 1-(4-methoxyphenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

- 15 (S)- 1-(4-fluorophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)- 1-(3-fluorophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)- 1-(4-cyanophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(R)- 1-(4-fluorophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)- 1-(3-cyanophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

- 20 (S)- 1-(4-bromo-2-cyanophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)- 1-(4-(difluoromethoxy)phenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)- 1-(3-(difluoromethoxy)phenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)- 1-(4-cyano-2-fluorophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)- 1-(4-cyano-3-fluorophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

- 25 (S)- 1-(2-cyano-4-fluorophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)- N-(4-(morpholin-2-yl)phenyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazole-4-carboxamide

~~(R)-1-(4-(difluoromethoxy)phenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide~~

~~(S)-1-(4-(difluoromethoxy)phenyl)-5-methyl-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide~~

~~(S)-1-(4-(difluoromethoxy)phenyl)-3-methyl-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide~~


~~(S)-1-(4-cyanophenyl)-5-methyl-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide~~

~~(R)-1-(4-cyano-2-fluorophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide~~

~~(RS)-1-(4-difluoromethoxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-pyrrolidin-3-yl-phenyl)-amide or~~


~~(RS)-1-(4-difluoromethoxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-piperidin-3-yl-phenyl)-amide.~~

42. A compound of formula IB according to claim 1,



IB

wherein



is pyridine-2, 3 or 4-yl;

R^2 is hydrogen or C_{1-7} -alkyl;

R^3 is hydrogen, amino or C_{1-7} -alkyl;

R^5 is hydrogen, halogen, C_{1-7} -alkyl, C_{3-6} -cycloalkyl, cyano, C_{1-7} -alkyl substituted by halogen, C_{1-7} -alkyl substituted by hydroxy, C_{1-7} -alkoxy, C_{1-7} -alkoxy substituted by halogen, C_{1-7} -alkoxy substituted by hydroxy;

n is 1 or 2;

Z is a bond, $-CH_2-$ or $-O-$;

or a pharmaceutically suitable acid addition salt thereof.

53. A compound according to any one of claims 1 or 42, wherein the compounds are

(S)-1-(5-chloropyridin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(5-cyanopyridin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

5 (S)-1-(5-bromopyridin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(5-iodopyridin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-N-(4-(morpholin-2-yl)phenyl)-1-(5-(trifluoromethyl)pyridin-2-yl)-1H-pyrazole-4-carboxamide

(S)-N-(4-(morpholin-2-yl)phenyl)-1-(4-(trifluoromethyl)pyridin-2-yl)-1H-pyrazole-4-

10 carboxamide

(S)-1-(4-chloropyridin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(2-bromopyridin-4-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(6-methoxypyridin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-

15 carboxamide


(S)-1-(2-chloropyridin-4-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(6-ethoxypyridin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-N-(4-(morpholin-2-yl)phenyl)-1-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide or

20 (S)-N-(4-(morpholin-2-yl)phenyl)-1-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazole-4-carboxamide.

64. A compound of formulas IC1, IC2 and IC3 according to claim 1,



wherein

R^2 is hydrogen or C_{1-7} -alkyl;

5 R^3 is hydrogen, amino or C_{1-7} -alkyl;

R^6 is hydrogen, halogen, C_{1-7} -alkyl, C_{3-6} -cycloalkyl, C_{1-7} -alkyl substituted by halogen or C_{1-7} -alkyl substituted by hydroxy;

Z is a bond, $-CH_2-$ or $-O-$;

or a pharmaceutically suitable acid addition salt thereof.

10

75. A compound according to any one of claims 1 or 64, wherein the compounds are
 (S)-1-(5-chloropyrimidin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide
 (S)-N-(4-(morpholin-2-yl)phenyl)-1-(2-(trifluoromethyl)pyrimidin-4-yl)-1H-pyrazole-4-
 carboxamide

15 (S)-1-(2-chloropyrimidin-4-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide
 (S)-N-(4-(morpholin-2-yl)phenyl)-1-(5-(trifluoromethyl)pyrimidin-2-yl)-1H-pyrazole-4-
 carboxamide

(S)-1-(4-methylpyrimidin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide


20 (S)-N-(4-(morpholin-2-yl)phenyl)-1-(6-(trifluoromethyl)pyrimidin-4-yl)-1H-pyrazole-4-
 carboxamide

(S)-N-(4-(morpholin-2-yl)phenyl)-1-(2-(trifluoromethyl)pyrimidin-5-yl)-1H-pyrazole-4-carboxamide or

(S)-N-(4-(morpholin-2-yl)phenyl)-1-(4-(trifluoromethyl)pyrimidin-2-yl)-1H-pyrazole-4-carboxamide.

5 (S)-1-(6-cyclopropylpyrimidin-4-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide.

86. A compound of formulas ID according to claim 1,



wherein

10 R^2 is hydrogen or C_{1-7} -alkyl;

R^3 is hydrogen, amino or C_{1-7} -alkyl;

R^7 is hydrogen, halogen, C_{1-7} -alkyl, C_{3-6} -cycloalkyl, C_{1-7} -alkyl substituted by halogen, C_{1-7} -alkyl substituted by hydroxyl or cyano;

Z is a bond, $-CH_2-$ or $-O-$;

15 or a pharmaceutically suitable acid addition salt thereof.

97. A compound according to any one of claims 1 or 86, wherein the compounds are (S)-N-(4-(morpholin-2-yl)phenyl)-1-(6-(trifluoromethyl)pyrazin-2-yl)-1H-pyrazole-4-carboxamide

20 (S)-1-(6-methylpyrazin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(5-methylpyrazin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(3-chloropyrazin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide


(S)-1-(5-cyanopyrazin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(5-chloropyrazin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

25 (S)-1-(6-cyanopyrazin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(3-cyanopyrazin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide or (S)-N-(4-(morpholin-2-yl)phenyl)-1-(5-(trifluoromethyl)pyrazin-2-yl)-1H-pyrazole-4-carboxamide.

5 ~~108~~. A compound of formulas IE according to claim 1,



wherein

R^2 is hydrogen or C_{1-7} -alkyl;

R^3 is hydrogen, amino or C_{1-7} -alkyl;


10 Z is a bond, $-CH_2-$ or $-O-$;

or a pharmaceutically suitable acid addition salt thereof.

~~119~~. A compound according to any one of claims 1 or ~~108~~, wherein the compound is (S)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-

15 carboxamide.

~~1210~~. A compound of formula IF according to claim 1



wherein

20 R^2 is hydrogen or C_{1-7} -alkyl;


R^3 is hydrogen, amino or C_{1-7} -alkyl

Z is a bond, $-CH_2-$ or $-O-$;


or a pharmaceutically suitable acid addition salt thereof.

- 5 ~~1311~~. A compound according to any one of claims 1 or ~~1210~~, wherein the compound is (S)-N-(4-(morpholin-2-yl)phenyl)-1-(4-(trifluoromethyl)thiazol-2-yl)-1H-pyrazole-4-carboxamide.

- ~~1412~~. A process for the manufacture of a compound of formula I according to any one of
10 claims 1 - ~~1311~~, which process comprises
cleaving off the protecting group of compounds of formula



to form a compound of formula I



- 15 and, if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts, wherein the substituents are as described in claim 1.

~~15. A compound according to any one of claims 1 - 13, when manufactured by a process according to claim 14.~~

~~16~~13. A pharmaceutical composition comprising a compound according to any one of claims 1 –~~13~~11 and a pharmaceutical acceptable carrier and/or adjuvant.

~~17~~14. A pharmaceutical composition according to claim ~~16~~2
5 comprising a compound according to any one of claims 1 –~~13~~11 and a pharmaceutical acceptable carrier and/or adjuvant for use in the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance
10 abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

15 ~~18~~15. Compounds according to any one of claims 1 –~~13~~11 for use as therapeutic active substances.

~~19~~16. Compounds according to any one of claims 1 –~~13~~11 for use in the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD),
20 stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular
25 disorders.

~~20~~17. The use of a compound according to any one of claims 1 –~~13~~11 for the preparation of medicaments for the therapeutic and/or prophylactic treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related
30 disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of